Vitara Biomedical
Philadelphia, US · Founded 2019 · Delaware corporation · 65 employees on LinkedIn · 4 known investors
Find your way into Vitara Biomedical
8 people in our graph share verified history with the Vitara Biomedical team — schools, employers, funds. One of them is your warm intro.
Matt Kerriganunlockedknows James McGlone · together at Metis (overlapped)
×4knows the team · via Fuji Xerox
×3knows the team · via Metis
Vitara Biomedical develops medical technology for the care of extremely premature newborns. The company is rooted in neonatology research from Children's Hospital of Philadelphia.
Founders & leadership
BL
Bernard LyonsinMember Board Of Directors
JM
James McGloneinSoftware Verification ManagerJames McGlone is an Executive Officer and Director at Vitara Biomedical, where he oversees software verification for regulated biomedical devices supporting neonatal care technology. He has experience in software testing, embedded systems, and cross-functional coordination across engineering, quality, and clinical workflows.
JK
Jeffrey KahnExecutive
Board
TT
Thomas TodorowBoard director
IR
Ian RatcliffeBoard director
MK
DN
Diem NguyenBoard director
TF
Ted FjallmanBoard director
AD
Arthur DantchikBoard director
AF
NH
Nelson HillBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$70M disclosed across 3 rounds · 2020–2024
▶$10MraisedOct 2024 · 9 investors · BiotechnologyRule 506(b)
▶$10MraisedOct 2024 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas TodorowDirector
- Ian RatcliffeDirector
- Manish KothariDirector
- Bernard LyonsExecutive Officer, Director
- Diem NguyenDirector
- Ted FjallmanDirector
- Offering amount
- $50M
- Amount sold
- $10M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$40MraisedDec 2023 · 9 investors · BiotechnologyRule 506(b)
▶$40MraisedDec 2023 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Diem NguyenDirector
- Manish KothariDirector
- Thomas TodorowDirector
- Ted FjallmanDirector
- Rosaleen OskanianExecutive Officer
- Bernard LyonsDirector
- James McGloneExecutive Officer, Director
- John KellyExecutive Officer
- Ian RatcliffeDirector
- Offering amount
- $90M
- Amount sold
- $40M
- Minimum investment
- $59K
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$20MraisedMay 2020 · 3 investors · BiotechnologyRule 506(b)
▶$20MraisedMay 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arthur DantchikDirector
- James McGloneExecutive Officer, Director
- Jeffrey KahnExecutive Officer
- Thomas TodorowDirector
- Diem NguyenDirector
- Nelson HillDirector
- Offering amount
- $30M
- Amount sold
- $20M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Vitara Biomedical went on to found or lead other companies.
Competitors · 5
by search overlap
Certara7 shared keywordsCertara provides biosimulation software, modeling, and regulatory services that support drug discovery and development across discovery, preclinical, clinical, regulatory, and market access phases. It serves pharmaceutical and biotech organizations seeking to make data-driven decisions and streamline regulatory submissions.
Bioworld7 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Vitro Biopharma6 shared keywordsVitro Biopharma is a biotechnology company developing Wharton's jelly-derived (umbilical cord) mesenchymal stem cell therapies for autoimmune diseases and inflammatory disorders. It manufactures its cell therapy product candidates under cGMP conditions with ISO 9001:2015 and ISO 13485:2016 certification for the immunology and inflammation market.
VISTERRA, INC.6 shared keywordsA biologics center of excellence focused on developing and delivering medicines to patients, operating as a subsidiary within the Otsuka pharmaceutical group.
Viridian Therapeutics6 shared keywordsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
Companies competing with Vitara Biomedical for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Vitara Biomedical do?
- Vitara Biomedical develops medical technology for the care of extremely premature newborns. The company is rooted in neonatology research from Children's Hospital of Philadelphia.
- Who are Vitara Biomedical's investors?
- Vitara Biomedical's investors include First Spark Ventures, Llc, Jazzya Investments, Khosla Ventures, Myelin VC.
- How much funding has Vitara Biomedical raised?
- Vitara Biomedical has disclosed $70M raised across 3 rounds.
- Where is Vitara Biomedical headquartered?
- Vitara Biomedical is headquartered in Philadelphia, US.